← Product Code [JWH](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH) · K093746 # VERILAST WEAR CLAIMS FOR THE LEGION PRIMARY KNEE SYSTEM (K093746) _Smith & Nephew, Inc. · JWH · Apr 14, 2010 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH/K093746 ## Device Facts - **Applicant:** Smith & Nephew, Inc. - **Product Code:** [JWH](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH.md) - **Decision Date:** Apr 14, 2010 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3560 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use Total knee components are indicated for rheumatoid arthritis; post-traumatic arthritis, osteoarthritis, or degenerative arthritis in older patients whose age, weight, and activity level are compatible with an adequate long-term result; failed osteotomies, unicompartmental replacement, or total knee replacement. Posterior stabilized knee systems are designed for use in patients in primary and revision surgery, where the anterior and posterior cruciate ligaments are absent or incompetent and the collateral ligaments remain intact. Smith & Nephew, Inc. Legion Primary Knee components are indicated for use only with cement and are single use devices. ## Device Story The LEGION Primary Knee System is a total knee prosthesis consisting of an Oxinium femoral component and a 7.5 Mrad cross-linked polyethylene (XLPE) articular insert. The device is intended for cemented, single-use implantation in patients undergoing total knee arthroplasty. This submission specifically establishes long-term in vitro wear claims for the existing implant components. The device is used by orthopedic surgeons in a clinical/surgical setting. The system functions as a mechanical bearing couple; the Oxinium/XLPE interface is designed to exhibit low wear characteristics. Clinical decision-making is supported by the established safety and effectiveness of the existing components, with the new wear claims providing information on long-term durability. The patient benefits from a reduced rate of wear, potentially extending the lifespan of the knee replacement. ## Clinical Evidence No clinical data was used to support the safety and effectiveness of the device. Evidence is based on in vitro knee simulator wear testing, which demonstrated that the OXINIUM/XLPE bearing couple exhibits low wear characteristics compared to a control system. The document notes that in vitro wear simulation results have not been proven to quantitatively predict clinical wear performance. ## Technological Characteristics System comprises Oxinium (oxidized zirconium) femoral components and 7.5 Mrad cross-linked polyethylene (XLPE) articular inserts. Designed as a semi-constrained, cemented, single-use total knee prosthesis. No new materials or fundamental technological changes; modifications include geometric adjustments to the femoral box and condyles. Connectivity: N/A. Sterilization: Not specified. ## Regulatory Identification A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027). ## Predicate Devices - Genesis II & Profix Zirconium Femoral Knee Components ([K962557](/device/K962557.md)) - Crosslinked Polyethylene Articular Inserts ([K071071](/device/K071071.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K093746 # Summary of Safety and Effectiveness VERILAST® Wear Claims for the LEGION* Primary Knee System Smith & Nephew, Inc. ### Contact Person and Address Jason Sells Manager, Regulatory Affairs Smith & Nephew, Inc. Orthopaedic Division 1450 East Brooks Road Memphis, Tennessee 38116 T (901) 399-5520 Date of Summary: April 14, 2010 4/14/2010 Name of Device: LEGION® Primary Knee System Common Name: Total Knee Prosthesis Device Classification Name and Reference: 21 CFR 888.3560 Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis Device Class: Class II Panel Code: Orthopaedics/87 JWH Predicate Devices: Genesis II & Profix Zirconium Femoral Knee Components (K962557); and Crosslinked Polyethylene Articular Inserts (K071071) ### Device Description Subject of this Traditional 510(k) Premarket Notification is a request for long-term in vitro wear claims for the Smith & Nephew, Inc. Legion Primary Knee System. The wear claims will be made for the use of a Legion Primary Oxinium femoral component coupled with a 7.5 Mrad cross-linked polyethylene (XLPE) articular insert. The Legion Primary Knee System consists of existing total knee implant devices, and it is important to note that there are no new total knee components being introduced as a result of this Traditional 510(k) premarket notification. ### Intended Use Total knee components are indicated for rheumatoid arthritis; post-traumatic arthritis, or degenerative arthritis in older patients whose age, weight, and activity level are compatible with an adequate long-term result; failed osteotomies, unicompartmental replacement, or total knee replacement. Posterior stabilized knee systems are designed for use in patients in primary and revision surgery, where the anterior and posterior cruciate ligaments are absent or incompetent and the collateral ligaments remain intact. Smith & Nephew, Inc. Legion Primary Knee components are indicated for use only with cement and are single use devices. ### Performance Data In vitro knee simulator wear testing provided in the submission demonstrated that the OXINIUM?/XLPE bearing couple exhibited low wear characteristics in long-term laboratory testing as compared to a control total knee system. The results of in-vitro wear simulation testing have not been proven to quantitatively predict clinical wear performance. Clinical data was not needed to support the safety and effectiveness of the subject device. {1}------------------------------------------------ # Substantial Equivalence Information The Legion Primary Knee System consists of existing total knee implants currently marketed by Smith & Nephew. The femoral implant components are substantially equivalent to the Genesis II Oxinium femoral components cleared via K962557. The following, minor modifications were made to the Genesis II Oxinium femoral components in order to develop the subject devices: - l Increased the thickness of the medial posterior condyle to match that of the lateral posterior condyle - Addition of threaded screw holes for wedge attachment (posterior stabilized design only) I - Addition of anterior wall to femoral box geometry (posterior stabilized design only) ■ - 트 Increased in height of femoral box geometry (posterior stabilized design only) The subject femoral components are used with existing Legion articular inserts' cleared via K071071. ## Conclusion As previously noted, this Traditional 510(k) Premarket Notification is being submitted to request clearance for long-term wear claims for the Smith & Nephew, Inc. Legion Primary Knee System. As no new total knee components are being introduced as a result of this premarket notification, the devices are substantially equivalent to knee components currently marketed under K962557 and K071071. 1 The Genesis II cross-linked polyethylene IXLPE) articular inserts cleared via K071071 are marketed by Smith & Nephew under the Legion brand name. 2/2 {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 # APR 1 4 2010 Smith & Nephew, Inc. % Mr. Jason Sells 1450 E Brooks Road Memphis. Tennessee 38116 Re: K093746 Trade/Device Name: LEGION Primary Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis Regulatory Class: II Product Code: JWH Dated: April 8, 2010 Received: April 9, 2010 Dear Mr. Sells: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but.not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {3}------------------------------------------------ Page 2 - Mr. Jason Sells forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely vours. Barbara Brem Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ Indications for Use 510(k) Number (if known). K093746 Device Name: LEGION® Primary Knee System Indications for Use: Total knee components are indicated for rheumatoid arthritis; post-traumatic arthritis, osteoarthritis, or degenerative arthritis in older patients whose age, weight, and activity level are compatible with an adequate long-term result; failed osteotomies, unicompartmental replacement, or total knee replacement. Posterior stabilized knee systems are designed for use in patients in primary and revision surgery, where the anterior and posterior cruciate ligaments are absent or incompetent and the collateral ligaments remain intact. Smith & Nephew, Inc. Legion Primary Knee components are indicated for use only with cement and are single use devices. Prescription Use x AND/OR (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 807 Subpart C) IPLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED] Concurrence of CDRH, Office of Device Evaluation (ODE) Anita for MXM bedic. and Rest Page 1 of 510(k) Number K093746 --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH/K093746](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/JWH/K093746) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com